Insmed Incorporated awarded inducement grants to 128 new employees as part of its 2025 Inducement Plan to attract talent. The awards include 115,320 restricted stock units and options to purchase 5,560 shares at $121.82 each, with vesting schedules over four years for stock units and options lasting ten years. This move supports Insmed's growth in biopharmaceuticals, focusing on therapies for serious diseases. The company continues to advance its portfolio in respiratory, immunology, and rare diseases with innovative technologies.
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...
RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...
Lululemon Athletica's shares fell about 18% after the company lowered its full-year financial forecast for the second time, reflecting ongoing challenges. In Q2 2026, total net revenue dropped 4% to $2.40 billion, with a 10% fall in comparable sales ...
Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intest...
